Showing 86 of 86on this page. Filters & sort apply to loaded results; URL updates for sharing.86 of 86 on this page
BioAtla Announces Upcoming Poster Presentation at the 39th Society for ...
BioAtla (BCAB) - Market capitalization
BioAtla rakes in $72.5M Series D, advancing research for pH-detecting ...
BioAtla Axes 70% of Staff, Exploring Strategic Options Amidst Industry ...
Conditionally Active Biologics™ (CAB) - BioAtla
BioAtla (BCAB.O) Plummets 15% Intraday—What’s Behind the Sudden Drop?
BioAtla August 2025 slides: promising clinical data amid financial ...
BioAtla Virtual R&D Day: BA3071 CAB-CTLA-4 Phase 1 Data Review in ...
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M ...
BioAtla to Complete Merger with BA Merger Sub on April 6
BioAtla Investor Presentation Deck | Slidebook.io
BioAtla IPO Presentation Deck | Slidebook.io
BioAtla posts 2025 loss, starts strategic review | BCAB 8-K Filing
BioAtla (BCAB) sets $40M SPV to fund Phase 3 Oz-V OPSCC trial | BCAB ...
BioAtla Reports $69.8 Million Net Loss in 2024 with Promising Clinical ...
BioAtla (BCAB.O) Plunges 15%—What’s Behind the Sharp Move?
BioAtla plans 1-for-50 reverse split to support Nasdaq | BCAB SEC ...
BioAtla Employee Perks & Benefits | Levels.fyi
BioAtla (BCAB|$17.7M) - 2024 Q4 & Full Year Earnings Analysis - YouTube
BioAtla & GATC Health: Oz-V Phase III Oncology Trial
BioAtla pursues strategic review, cancer pipeline focus | BCAB Annual ...
Impressive Survival Data Sparks Rally for BioAtla Shares - Stocks Today
BCAB Stock Price, News & Analysis | Bioatla
BioAtla and GATC Health Announce $40M SPV Transaction to Advance ...
BioAtla Inc. (BCAB) | IPO 2020
Инвест обзор IPO BioAtla (BCAB) - YouTube
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC ...
BioAtla Reports 21.5-Month Median OS in Refractory Sarcomas | BCAB ...
Yong Ben appointed Chief Medical Officer of BioAtla - Pharma Journalist
BioAtla (BCAB) Investor Presentation - Slideshow (NASDAQ:BCAB) 2023-05 ...
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Increase in Short Interest ...
BioAtla_百度百科
BioAtla, Inc. (BCAB) BCG Matrix Analysis – DCFmodeling.com
国外Biotech公司ADC产品技术特色医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
国外Biotech公司ADC产品技术特色
BCAB Q3 2025 Earnings Report on 11/13/2025
BCAB Q2 2025 Earnings Report on 8/7/2025
What Is BioAtla’s IPO Date and Price?
CAB-AXL-ADC新药早期临床结果积极，BioAtla盘前飙升47%医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Bioatla宣布CAB-AXL-ADC產品IND申請獲得FDA批准丨醫麥優企秀 - 每日頭條
Work in San Diego, CA - San Diego: Life. Changing.
Logos of biotech companies
BioAtla’s Ozuriftamab Vedotin Receives FDA Fast Track Designation for ...
BioAtla条件性pH激活抗 EpCAM x CD3 双特异性抗体设计 - 知乎
BCAB Q4 2024 Earnings Report on 3/27/2025
Effective Presentation Design for BioAtla's Cancer Therapy Innovations ...
BCAB Q1 2023 Earnings Report on 5/11/2023
Bridgewest Group: Empowering people through business investment
Melanoma investor presentations and pitch decks | Slidebook
BioAlta Yorkville
Buy BioAtla, Inc Stock – BCAB Stock Quote Today & Investment Insights ...
BCAB Q3 2024 Earnings Report on 11/7/2024
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) | Seeking Alpha
BioAtla, Inc. (BCAB) Stock Price, Quote, News & Analysis | Seeking Alpha
Weekly Digest - 26 December to 02 January 2026 - Optimal Dose
BCAB Q1 2025 Earnings Report on 5/6/2025
%201.jpg)
